60 Degrees: IRB OKs Phase IIA Study for Babesiosis Tick-Borne Disease; FDA Type C Meeting Re-Scheduled

 

•  Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients
• The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15 to January 17, 2024, due to a federal holiday

https://www.globenewswire.com/news-release/2023/12/26/2801070/0/en/60-Degrees-Pharma-Announces-IRB-Approval-of-Phase-IIA-Study-to-Evaluate-Tafenoquine-for-Babesiosis-an-Emerging-Tick-Borne-Disease-Type-C-Meeting-Re-Scheduled-by-FDA-to-January-17-2.html